Cells were plated on culture plates either not coated (control) or pre-coated with rhDLL1-Fc, for the induction of DLL1-Notch target genes, or Fc protein in the absence or presence of Dl1.72, Ctr Ab, DAPT, or DMSO, as indicated elsewhere. Total RNA was extracted using the
RNeasy Mini kit (Qiagen, La Jolla, CA, USA, #50974104), and cDNA was generated from equal amounts of RNA by reverse transcription using the
Advantage RT-for-PCR kit (Clontech Laboratories, Mountain View, CA, USA, # 639506), as per the manufacturer’s instructions. The expression of
HEY-1,
HEY-L,
HPRT1,
RPL22,
SOX2 and
SOX9 genes was quantified on Roche
LightCycler 480 equipment using
SYBR Green I Master Kit (Roche, Bazel, Switzerland). mRNA transcripts were normalized to housekeeping genes
HPRT1 and
RPL22 levels in the same sample, and the results were calculated as fold change relative to control cells, as previously described [24 (
link)]. The primers used in these assays are listed in
Table S2.
Silva G., Sales-Dias J., Casal D., Alves S., Domenici G., Barreto C., Matos C., Lemos A.R., Matias A.T., Kucheryava K., Ferreira A., Moita M.R., Braga S., Brito C., Cabral M.G., Casalou C., Barral D.C., Sousa P.M., Videira P.A., Bandeiras T.M, & Barbas A. (2021). Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy against Estrogen Receptor-Positive Breast Cancer. Cancers, 13(16), 4074.